This article reviews the discovery of PCSK9, its structure–function characteristics, and its
presently known and proposed novel biological functions. The major critical function of …

Non-alcoholic fatty liver disease (NAFLD) is a quickly emerging global health problem
representing the most common chronic liver disease in the world. Atherosclerotic …

Despite its success in achieving the long-term survival of 10–30% of treated individuals,
immune therapy is still ineffective for most patients with cancer,. Many efforts are therefore …

The gene encoding PCSK9 was first identified and linked to the phenotype of familial
hypercholesterolaemia approximately 15 years ago. Soon after, studies uncovered the role …

Animal studies are a foundation for defining mechanisms of atherosclerosis and potential
targets of drugs to prevent lesion development or reverse the disease. In the current …

It is now about 20 years since the first case of a gain-of-function mutation involving the as-yet-
unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …

Bile acids are the end products of cholesterol catabolism. Hepatic bile acid synthesis
accounts for a major fraction of daily cholesterol turnover in humans. Biliary secretion of bile …

Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into
mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies …

The mammalian proprotein convertases constitute a family of nine secretory serine
proteases that are related to bacterial subtilisin and yeast kexin. Seven of these (proprotein …